Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Joshua Brown of Ritholtz Wealth Management said under $30, Pfizer Inc. PFE is a gift.

Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform under the brand "Pfizer for All."

Jim Lebenthal of Cerity Partners said QUALCOMM Incorporated QCOM is breaking out right now.

On May 14, Qualcomm and Aramco reported a collaboration that includes accelerating development of industrial 4G/5G NGN ecosystem.

Don't forget to check out our premarket coverage here

Sarat Sethi of DCLA said Freeport-McMoRan Inc. FCX is a copper play, and demand for copper is going through the roof.

On April 23, Freeport said first-quarter revenue stood at $6.32 billion, beating the consensus of $5.66 billion. Adjusted EPS was 32 cents, beating the consensus of 27 cents.

Amy Raskin of Chevy Chase Trust named Vertex Pharmaceuticals Incorporated VRTX as her final trade.

On May 6, Vertex Pharmaceuticals posted stronger-than-expected results for its first quarter.

Price Action:

• Pfizer shares fell 0.2% to close at $28.38 on Tuesday.
• Qualcomm gained 2.6% to settle at $188.97 during Tuesday's session.
• Freeport-McMoRan shares rose 2.8% to settle at $53.48 on Tuesday.
• Vertex Pharmaceuticals shares slipped 0.3% to close at $428.59 on Tuesday.

Check This Out: Cisco, Prestige Consumer Healthcare And 3 Stocks To Watch Heading Into Wednesday

Image: Shutterstock